Literature DB >> 19732687

Breast conservation therapy for patients with locally advanced breast cancer.

Mohamed A Alm El-Din1, Alphonse G Taghian.   

Abstract

Neoadjuvant chemotherapy achieves high response rates in patients with breast cancer and has been used to reduce tumor size and allow for breast conservation in individuals who initially required mastectomy. The goals of this approach are to achieve optimal locoregional control together with acceptable cosmesis. In the setting of locally advanced disease, breast preservation appears to be feasible for appropriately selected patients whose tumors show adequate downstaging in response to induction chemotherapy. Nevertheless, further prospective randomized trials are warranted to better evaluate the results of this approach as compared with mastectomy.

Entities:  

Mesh:

Year:  2009        PMID: 19732687     DOI: 10.1016/j.semradonc.2009.05.005

Source DB:  PubMed          Journal:  Semin Radiat Oncol        ISSN: 1053-4296            Impact factor:   5.934


  7 in total

1.  Role of plasma osteopontin as a biomarker in locally advanced breast cancer.

Authors:  Pieter H Anborgh; Laura Br Caria; Ann F Chambers; Alan B Tuck; Larry W Stitt; Muriel Brackstone
Journal:  Am J Transl Res       Date:  2015-04-15       Impact factor: 4.060

2.  Ultrasound ablation enhances drug accumulation and survival in mammary carcinoma models.

Authors:  Andrew W Wong; Brett Z Fite; Yu Liu; Azadeh Kheirolomoom; Jai W Seo; Katherine D Watson; Lisa M Mahakian; Sarah M Tam; Hua Zhang; Josquin Foiret; Alexander D Borowsky; Katherine W Ferrara
Journal:  J Clin Invest       Date:  2015-11-23       Impact factor: 14.808

Review 3.  Extent of primary breast cancer surgery: standards and individualized concepts.

Authors:  Joerg Heil; Valerie Fuchs; Michael Golatta; Sarah Schott; Markus Wallwiener; Christoph Domschke; Peter Sinn; Michael P Lux; Christof Sohn; Florian Schütz
Journal:  Breast Care (Basel)       Date:  2012-10       Impact factor: 2.860

4.  Post-chemotherapy target volumes are safe as boost volume for intact breast radiotherapy in locally advanced breast cancer.

Authors:  Sushma Agrawal; Waseem Raza; Punita Lal; K J Maria Das; Gaurav Agarwal
Journal:  Rep Pract Oncol Radiother       Date:  2020-02-21

5.  De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer.

Authors:  Xiwei Wu; George Somlo; Yang Yu; Melanie R Palomares; Arthur Xuejun Li; Weiying Zhou; Amy Chow; Yun Yen; John J Rossi; Harry Gao; Jinhui Wang; Yate-Ching Yuan; Paul Frankel; Sierra Li; Kimlin Tam Ashing-Giwa; Guihua Sun; Yafan Wang; Robin Smith; Kim Robinson; Xiubao Ren; Shizhen Emily Wang
Journal:  J Transl Med       Date:  2012-03-08       Impact factor: 5.531

6.  Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice.

Authors:  Domenico Angelucci; Nicola Tinari; Antonino Grassadonia; Ettore Cianchetti; Giampiero Ausili-Cefaro; Laura Iezzi; Marinella Zilli; Simona Grossi; Lucia Anna Ursini; Maria Teresa Scognamiglio; Graziella Castrilli; Michele De Tursi; Paolo Noccioli; Pasquale Cioffi; Stefano Iacobelli; Clara Natoli
Journal:  J Cancer Res Clin Oncol       Date:  2012-10-10       Impact factor: 4.553

7.  DEGRO practical guidelines for radiotherapy of breast cancer V: Therapy for locally advanced and inflammatory breast cancer, as well as local therapy in cases with synchronous distant metastases.

Authors:  Wilfried Budach; Christiane Matuschek; Edwin Bölke; Jürgen Dunst; Petra Feyer; Rainer Fietkau; Wulf Haase; Wolfgang Harms; Marc D Piroth; Marie-Luise Sautter-Bihl; Felix Sedlmayer; Rainer Souchon; Frederik Wenz; Frederick Wenz; Rolf Sauer
Journal:  Strahlenther Onkol       Date:  2015-05-12       Impact factor: 3.621

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.